Abstract
Conventional wisdom is that biotech floatations in Europe belong on the London stock market. But the CEO of the Swiss stock exchange is bullish about the advantages of his exchange for life science ventures.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
